United States Senators Urge DOJ and FDA for E-cigarette Enforcement

Regulations by 2FIRSTS.ai
Jul.09.2024
United States Senators Urge DOJ and FDA for E-cigarette Enforcement
Senators Demand More Information on Crackdown on Unauthorized E-Cigarette Sales by Multi-Agency Task Force, Expressing Concerns Over Inconsistencies in Statements.

According to a report from the Sierra Sun Times on July 8th, last week, US Senator Susan Collins and her bipartisan colleagues wrote to senior officials at the Department of Justice (DOJ) Consumer Protection Division and the US Food and Drug Administration (FDA) Center for Tobacco Products, requesting more information about the recently announced interagency task force to combat unauthorized e-cigarette sales and distribution.

 

The letter also reiterated the importance of restoring the pre-market review process required by federal law. The letter was co-signed by Senators Dick Durbin (D-IL), Mitt Romney (R-UT), Richard Blumenthal (D-CT), Jeff Merkley (D-OR), Thom Tillis (R-NC), Mazie Hirono (D-HI), and Ron Wyden (D-OR).

 

The senators wrote,

 

We appreciate the recent announcement of the establishment of a federal task force to enhance enforcement of these illegal and dangerous products through the collaboration of the FDA, Department of Justice, Bureau of Alcohol, Tobacco, Firearms and Explosives, U.S. Marshals Service, U.S. Postal Inspection Service, and Federal Trade Commission. However, we remain deeply concerned about the inconsistency between the public statements of the FDA and DOJ, which claim that only 27 e-cigarette products have been authorized by the FDA, while in fact, thousands of unauthorized e-cigarettes with child-friendly flavors such as blueberry ice, strawberry watermelon bubblegum, and Red Bull strawberry are still readily available.

 

Clearly, the top priority of the working group should be to restore the pre-market review system for e-cigarettes and enforce the removal of all unauthorized e-cigarettes.

 

On June 10, 2024, the United States Department of Justice and the Food and Drug Administration announced the establishment of a federal multi-agency task force to combat the illegal distribution and sale of e-cigarettes. In addition to the FDA and the DOJ, this task force will also bring together multiple law enforcement agencies, utilizing all criminal and civil measures to crack down on illegal e-cigarette distribution and sale.

 

This letter also calls on the FDA to complete long-term reviews of premarket tobacco product applications submitted by e-cigarette manufacturers. Since the FDA missed the final deadline set by the court on September 9, 2021, over 2.1 million children may have already started using e-cigarettes. The FDA also missed another deadline to complete reviews of certain products by June 30, 2024. According to the Tobacco Control Act (TCA), e-cigarette companies must obtain FDA authorization before entering the market, a requirement that the FDA has failed to enforce.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
A cross-sectional analysis based on the US NHANES 2021–2023 cycle, including 6,262 participants aged over 12, found that compared with people who neither smoke nor vape, those who smoke and/or use e-cigarettes had a higher prevalence of elevated blood pressure and hypertension. After full adjustment, smoking/vaping was associated with elevated blood pressure (aOR 1.34) and hypertension (aOR 1.46), and with a 1.05 mmHg higher diastolic blood pressure.
Feb.09 by 2FIRSTS.ai
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
As the FDA advances efforts to streamline its PMTA review process, including support for small businesses, expectations are rising that additional product authorizations may follow. Age-verification technology is emerging as a key consideration in future approvals.In this interview, California-based Glas discusses its G2 platform, integrating smartphone-based identity verification, proximity controls and anti-counterfeit systems, and outlines its positioning under the FDA’s PMTA framework.
Mar.02
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11
3,200 suspected "drug-laced cigarettes" seized in Johor Bahru, case value estimated at US$242,500
3,200 suspected "drug-laced cigarettes" seized in Johor Bahru, case value estimated at US$242,500
Malaysian police seized 3,200 suspicious e-pods with ketamine liquid, arresting two men in Johor Bahru's drug distribution bust.
Feb.04 by 2FIRSTS.ai
New Zealand Vape Company Alt Becomes Government Partner After Suing Over Nicotine Limits
New Zealand Vape Company Alt Becomes Government Partner After Suing Over Nicotine Limits
Health NZ signed a NZD 500,000 contract with New Zealand-owned vape company Alt NZ Limited in December 2025 for its free vape kit programme for smokers, with more than 7,000 kits distributed so far.
Mar.23 by 2FIRSTS.ai
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
2Firsts has learned that France’s national health authority, the Haute Autorité de Santé (HAS), confirmed the role of e-cigarettes will be addressed in updated national smoking-cessation guidelines expected by the end of 2026. HAS said the recommendations will focus on clinical and public-health considerations, will not set technical standards for vaping products, and that current studies are insufficient to clearly assess risks and benefits across different product categories.
Mar.10